Effect of topical cyclosporine on tear functions in tear-deficient dry eyes

Annals of Ophthalmology

Volumn 39, Issue 1, 2007, Pages 19-25

  Jain, Arun K ^a   Sukhija, Jaspreet ^a   Dwedi, Sujata ^a   Sood, Archna ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY EYE; FEMALE; HUMAN; LACRIMATION DISORDER; MALE; RANDOMIZED CONTROLLED TRIAL; SCHIRMER TEST; SCORING SYSTEM; SJOEGREN SYNDROME; STATISTICAL ANALYSIS; TEAR FLOW; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; CROSS-OVER STUDIES; CYCLOSPORINE; DRY EYE SYNDROMES; FEMALE; HUMANS; LACRIMAL APPARATUS DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TEARS;

EID: 35648972661     PISSN: 15304086     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02697322     Document Type: Article

References (27)

1. Lemp MA. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAO J 1995;21:221-232.
2. Bron AJ. The Doyne lecture: reflections on the tears. Eye 1997;11:583-602.
3. Doughty MJ, Fonn D, Richter D, et al. A patient questionnaire approach to estimation of prevalence of dry eye symptoms in patients presenting to optometry practices across Canada. Optom Vis Sci 1997;74:624-631.
4. Lemp MA. Management of dry eye patient. Int Ophthalmol Clin 1994;34:101-113.
5. Stem ME, Beuerman RW, Fox RI, et al. The pathology of dry eye. The interaction between the ocular snrface and lacrimal gland. Cornea 1998;17:584-589.
6. Lemp MA. New strategies in the treatment of dry eye states. Cornea 1999;18:625-632.
7. Stevenson D, Tauber J, Reiss BL, et al. Efficacy and safety of cyclosporine A ophthalmic emulsion in the treatment of moderate to severe dry eye: a dose ranging, randomized trial. Ophthalmology 2000;107:967-974.
8. Turner K, Pflugfelder SC, Ji W, et al. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea 2000;l9:492-496.
9. Kunert KS, Tisdole AS, Gipson IK. Goblet cell numbers and epithelial cell proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol 2002;120:330-337.
10. Brignole F, Pisella PJ, Goldschild M, et al. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Invest Ophthalmol Vis Sci 2000;41:1356-1363.
11. Brignole F, Pisella PJ, Goldschild M, et al. Flow cyometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporine A. Invest Ophthalmol Vis Sci 2001;42:90-95.
12. Kunert KS, Tisdale AS, Stern, ME, Smith JA, Gipson IK. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol 2000;118:1489-1496.
13. Laibovitz RA, Solch S, Andriano K, et al. Pilot trial of cyclosporine l% ophthalmic ointment in the treatment of keratoconjuctivitis sicca. Cornea 1993;12:315-323.
14. Gunduz K, Ozden O. Topical cyclosporine treatment of keratoconjuctivitis sicca in secondary Sjögren's syndrome. Acta Ophthalmol 1994;72:438-42.
15. Sall K, Stevenson OD, Mundorf TK, et al. Two multicentric randomized. studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye. Ophthalmology 2000;107:631-639.
16. Vitali C, Bombardieri S, Haralampos M, et al. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective action supported by the European community. Arthritis Rheum 1993;36:340-347.
17. Roche KB, Munoz B, Tielsch JM, et al. Self reported assessment of dry eye in a population based setting. Invest Ophthalmol Vis Sci 1997;38:2469-2475.
18. Prabhasawat P, Tseng SCG. Frequent association of the delayed tear clearance in ocular irritation. Br J Ophthalmol 1998;82:666-675.
19. Van Bijsterveld OP. Diagnostic tests in the Sicca syndrome. Arch Opthalmol 1969;82:10-14.
20. Murdoch IE, Morris SS, Cousens SN. People and eyes: statistical approaches in Ophthalmology. Br J Ophthalmol 1998;82:971-973.
21. Gilbard JP, Rossi SR, Heyola KG, Dortt DA. Stimulation of tear secretion and treatment of dry eye disease with 3-isobutyl-1-methylxonthine. Arch Opthalmol 1991;109:672-676.
22. Benson Dr, Hemmady PB, Snyder RW. Efficacy of laser punctal occulsion. Ophthalmology 1992;99:618-621.
23. Borel JF. Cyclosporine. Historical perspectives. In: First International Congress on Cyclosporine. Kahan BD. ed. Orlando: Grune and Stralton 1984, pp. 3-13.
24. Emmel EA, Verveij CL, Durand DB, et al. Cyclosporine A specifically inhibits function of nuclear proteins involved in T cell activation. Science 1989;246:1617-1620.
25. Nussenblatt RB, Palestine AG. Cyclosporine: immunology, pharmacology and therapeutic uses. Surv Ophthalmol 1986;31:159-169.
26. Palmer SL, Bowen AB, Green Keith. Tear flow in cyclosporine recipients. Ophthalmology 1995;102:118-121.
27. Palmer SL, Bowen AB, Green K. Longitudinal tear study after cyclosporine in kidney transplant recepients. Ophthalmology 1996;103:670-673.